Semax — heptapeptide research compound based on ACTH(4-7). Russian-developed nootropic studied in neuroprotection research.

Semax is a heptapeptide research compound corresponding to ACTH(4-7) with a C-terminal Pro-Gly-Pro extension for stability. It was developed at the Institute of Molecular Genetics in Russia.
Semax has been studied to modulate BDNF, NGF, and other neurotrophic factors. It shows neuroprotective effects in research models without the corticosteroid effects of full-length ACTH.
Used in: neuroprotection research, nootropic studies, BDNF/NGF research, stroke research models.
| Compound | Semax |
| Available Strengths | 5mg, 10mg |
| Purity | ≥99% (verified by HPLC) |
| Form | Lyophilized powder |
| Storage | -20°C, protected from light |
| Reconstitution | Bacteriostatic water (sold separately) |
| Shelf Life | 36 months (lyophilized, properly stored) |
| Certificate of Analysis | Available upon request — contact us |
Add bacteriostatic water slowly. Use within 28 days.
Lyophilized: -20°C. Reconstituted: 2-8°C.
For research use only. Not for human consumption.